Phaseline

Targets › PIM3

PIM3 (Serine/threonine-protein kinase pim-3): drug programs, companies and trials

2 programs from 2 companies in 2 trials: 1 Phase 2, 1 Phase 1; Oncology; next expected readout Dec 2026.

Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation. May contribute to tumorigenesis through: the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), the regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. (UniProt, Q86V86)

Open in Phaseline: the race on PIM3, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Ryvu TherapeuticsMEN1703 (SEL24, Dapolsertib hydrochloride)
Dual inhibitor of PIM kinases and FLT3
PIM1, PIM2, PIM3, FLT3Phase 2Non-Hodgkin Lymphoma, B-cellDec 2026
Sumitomo Pharma AmericaNuvisertib (TP-3654)
PIM kinase inhibitor
PIM1, PIM2, PIM3Phase 1MyelofibrosisApr 2027

Conditions

Non-Hodgkin Lymphoma, B-cell (1) Myelofibrosis (1)

Modalities

mixed (1), small molecule (1)

Companies

Ryvu Therapeutics (1) Sumitomo Pharma America (1)

Related targets

PIM1 (2) PIM2 (2) FLT3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.